Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2013

View Archived Issues

Preventive effects of diabetes medications in combating stroke

First-in-human study of Dompe's rhNGF eye drops in healthy subjects

Novel biomarkers for early detection of renal cell carcinoma identified

SynBio begins dosing in phase III ErepoXen study

Vitamin D deficiency and its impact on inflammatory markers in patients with diabetic foot

Phase II results reported for ETC-1002 in patients with diabetes and dyslipidemia

Nippon Shinyaku plans to conduct clinical study of Duchenne muscular dystrophy treatment

New androgen receptor modulators patented by Eli Lilly

Roche and Genentech present new BACE1 inhibitors

Canadian researchers divulge novel protein kinase inhibitors for cancer

Orgenesis and ATMI enter into process development agreement for diabetes

Trevena and Forest Laboratories collaborate on TRV-027

Unigene and Nordic Bioscience enter license agreement for metabolic peptide analogues

Creabilis' topical Trk-A inhibitor CT-327 shows promise

Genmab's antibody-drug conjugate evaluated in vitro and in vivo

Oregon Therapeutics identifies compounds active against drug-resistant cancer cells

Novartis obtains FDA approval for Ilaris in active systemic juvenile idiopathic arthritis

Confirmatory phase III study of BromSite begins

Biotie reports initiation of NIH-funded study of nepicastat in cocaine dependence

Novel chimeric antigen receptors presented by HHS

Dose-escalation begins in phase I/II study of MyeloXen vaccine for multiple sclerosis

Adaptive Biotechnologies enters into biomarker collaboration with Bristol-Myers Squibb

Mitsubishi Tanabe Pharma: fiscal 2012 in review

Recothrom approved for use in children age 1 month or older

Amgen and Zhejiang Beta Pharma form joint venture in China

FDA approves Breo Ellipta for treatment of COPD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...